Seminars in Oncology
Volume 35, Issue 6 , Pages 561-568 , December 2008

Colon Cancer in Older Adults

  • Laura Raftery

      Affiliations

    • Corresponding Author InformationAddress correspondence to Laura Raftery, MD, Division of Hematology and Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, 3009 Old Clinic Building, CB 7305, Chapel Hill, NC 27599
    • ,
  • Hanna Kelly Sanoff
    • ,
  • Richard Goldberg

References 

  1. http://seer.cancer.gov/statfacts/. Accessed April 21, 2008.
  2. http://ecog.dfci.harvard.edu/general/perf-stat.html.
  3. Seeman TE, Berkman LF, Kohout F, et al. Intercommunity variations in the association between social ties and mortality in the elderly: a comparative analysis of three communities. Ann Epidemiol. 1993;3:325–335
  4. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25:1824–1831
  5. Townsley CA, Selby R, Siu LL, et al. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23:3112–3124
  6. Shayne M, Culakova E, Poniewierski MS, et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007;100:1611–1620
  7. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–358
  8. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastasic colon cancer. J Clin Oncol. 2004;22:23–30
  9. Andre T, Boni C, Mounedju-Boudiaf L, et al. Oxaliplatin, flourouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351
  10. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–237
  11. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastasic colorectal cancer: a multicentre randomized trial. Lancet. 2000;355:1041–1047
  12. de Gramont , Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947
  13. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan and FU/FA with or without cituximab in the first line treatment of patients with metastasis colorectal cancer. N Engl J Med. 2004;350:2335–2342
  14. Simmonds PD, Best L, George S, et al. Surgery for colorectal cancer in elderly patients: a systematic review. Lancet. 2000;356:968–974
  15. Sundarajan V, Mitra N, Jacobson JS. Survival associated with 5-flourouracil–based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002;136:349–7
  16. Hutchins L, Unger J, Crowley J, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol. 2002;20:2643–2650
  17. Sundararajan V, Mitra N, Jacobson J, Hutchins L, Unger J, Crowley J, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;347:233–239
  18. Schrag D, Cramer LD, Bach PB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer InstM. 2001;93:850–857
  19. Ayanian J, Zaslavsky A, Fuchs C, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21:1293–1300
  20. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444
  21. Jessup JM, Stewart A, Greene FL, et al. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age and differentiation. JAMA. 2005;294:2703–2711
  22. Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years of older. J Clin Oncol. 1999;17:2412–2418
  23. Delaunoit T, Goldberg RM, Sargent DJ, et al. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup trial N9741. Cancer. 2004;101:2170–2176
  24. Sargent D, Goldberg R, Jacobson S, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091–1097
  25. Folrecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastasis colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15:1330–1338
  26. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085–4091
  27. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21:2059–2069
  28. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol. 2006;24:394–400
  29. Figer A, Perez-Staub N, Carola E, et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer. 2007;110:2666–2671
  30. Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol. 2008;26:1443–1451
  31. Cunningham D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413–1418
  32. Sastre J, Marcuello E, Masutti B, et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. J Clin Oncol. 2005;23:3545–3551
  33. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine v intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) as first-line treatment in 605 patients with metastasis colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282–2292
  34. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097–4106
  35. Hochster HS, Welles L, Hart L, et al. Safety and efficacy of bevacizumab when added to oxaliplatin/fluoropyrimdine (O/F) regimens as first-line treatment of metastasis colorectal cancer: TREE 1& 2 studies [abstract]. J Clin Oncol. 2005;23:254a
  36. Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group study. J Clin Oncol. 2005;23:3104–3111
  37. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–1239
  38. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–1664
  39. Van Cutsem E, Lang I, D'haens G. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (MCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience [abstract]. J Clin Oncol. 2008;May 20 (suppl)
  40. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007;370:143–152
  41. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007;370:135–142
  42. Green E, Sargent D, Goldberg R, et al. Detailed analysis of oxaliplatin-associated neuro-toxicity in Intergroup trial N9741 [abstract 182]. 2005;Program and abstracts of the American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium, Hollywood, FL, January
  43. Fuchs CS, Marshall J, Mitchell E. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2005;25:4779–4786
  44. Maindrault-Goebel F, Lledo G, Chibaudel B. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC) (A GERCOR study [abstract]). J Clin Oncol. 2006;24:18S
  45. Dy GK, Krook JE, Green EM, et al. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol. 2007;25:3469
  46. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374–379

PII: S0093-7754(08)00187-5

doi: 10.1053/j.seminoncol.2008.08.004

Seminars in Oncology
Volume 35, Issue 6 , Pages 561-568 , December 2008

Article Tools